| URL | https://www.sandiegouniontribune.com/communities/n |
| Source | sandiegotribune.com |
| Date Published | 07/10/2023 |
| Author Name | Phil Diehl |
| Company/Division name | Gilead Sciences Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 132.5 |
| City reshored to: | Oceanside |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Infrastructure, Skilled workforce availability/training |